Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | USD 657.70B | 62.2x | 0.61 | USD 732.41 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.9% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | USD 365.65B | 26x | -0.45 | USD 151.73 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.4% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | USD 309.66B | 73.4x | -6.02 | USD 175.05 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.3% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | USD 283.78B | 18.7x | 0.86 | USD 64.73 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 239.63B | 24.6x | -0.84 | USD 38.10 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | USD 239.63B | 24.6x | -0.84 | USD 304.24 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | USD 202.98B | 28.7x | 1.59 | USD 66.29 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.6% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | USD 202.98B | 28.7x | 1.59 | USD 132.68 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | USD 200.35B | 17.8x | -0.97 | USD 107.52 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.3% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | USD 200.35B | 17.8x | -0.97 | USD 104.15 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | NYSE | Healthcare | Pharmaceuticals | USD 199.25B | 11.7x | 0 | USD 79.18 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.8% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | USD 153.76B | 37.5x | -0.95 | USD 285.98 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.2% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | USD 129.06B | 272.7x | -2.94 | USD 103.63 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | USD 124.62B | 20.4x | 6.79 | USD 51.50 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Pharmaceuticals | USD 124.34B | -246.3x | 2.02 | USD 484.22 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.7% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | USD 124.26B | 15.4x | 0.05 | USD 21.91 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | USD 103.18B | -13.8x | 0.05 | USD 50.71 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.3% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | USD 86.39B | 31.5x | -24.28 | USD 689.36 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.7% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 72.07B | 26.7x | 1.41 | USD 21.89 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CSL | OTC Markets | Healthcare | Pharmaceuticals | USD 70.93B | 25.4x | 2.31 | USD 74.60 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34% Upside | Upgrade to Pro+ | |
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | USD 68.65B | 20.6x | -0.42 | USD 17.32 | 6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | USD 68.65B | 20.6x | -0.42 | USD 34.64 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | USD 66.66B | 27.3x | 3.4 | USD 149.44 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.8% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 56.95B | 18x | -11.39 | USD 26.64 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.3% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | USD 44.23B | 25x | 0.6 | USD 10.06 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | USD 41.91B | 29.9x | 1.94 | USD 26.13 | -8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | USD 41.91B | 29.9x | 1.88 | USD 13.88 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 40.61B | 24.2x | 0.72 | USD 21.88 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | NYSE | Healthcare | Pharmaceuticals | USD 31.83B | 24.5x | 0.26 | USD 131.77 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.8% Upside | Upgrade to Pro+ | |
Alnylam | NASDAQ | Healthcare | Pharmaceuticals | USD 30.78B | -117.7x | -2.9 | USD 237.77 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.6% Upside | Upgrade to Pro+ | |
UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 28.82B | 23.8x | 0.11 | USD 77.48 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 24.46B | 10.7x | 0.06 | USD 23.69 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.5% Upside | Upgrade to Pro+ | |
Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | USD 22.50B | -8.9x | -0.59 | USD 5.90 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
Biogen | NASDAQ | Healthcare | Pharmaceuticals | USD 16.86B | 10.3x | 0.26 | USD 115.17 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | OTC Markets | Healthcare | Pharmaceuticals | USD 16.74B | USD 37.72 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.1% Upside | Upgrade to Pro+ | |||
Astellas Pharma Inc | OTC Markets | Healthcare | Pharmaceuticals | USD 15.83B | -42.9x | 0.03 | USD 8.88 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.3% Upside | Upgrade to Pro+ | |
Teva ADR | NYSE | Healthcare | Pharmaceuticals | USD 15.42B | -11.5x | 0.05 | USD 13.46 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Royalty Pharma | NASDAQ | Healthcare | Pharmaceuticals | USD 13.84B | 16.7x | -0.66 | USD 31.95 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.9% Upside | Upgrade to Pro+ | |
Shionogi ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 12.79B | 11x | 0.87 | USD 7.52 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
United Therapeutics | NASDAQ | Healthcare | Pharmaceuticals | USD 12.63B | 13x | 0.43 | USD 281.16 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.4% Upside | Upgrade to Pro+ | |
Incyte | NASDAQ | Healthcare | Pharmaceuticals | USD 11.01B | 354.1x | -3.58 | USD 56.87 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.8% Upside | Upgrade to Pro+ | |
Biomarin Pharma | NASDAQ | Healthcare | Pharmaceuticals | USD 10.84B | 25.1x | 0.17 | USD 56.82 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dr. Reddy’s Labs ADR | NYSE | Healthcare | Pharmaceuticals | USD 10.75B | 17.4x | 6.43 | USD 13.22 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
Neurocrine | NASDAQ | Healthcare | Pharmaceuticals | USD 9.06B | 26.7x | 0.8 | USD 90.87 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viatris | NASDAQ | Healthcare | Pharmaceuticals | USD 9B | -17.1x | 0.01 | USD 7.54 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 8.83B | 21.9x | -0.47 | USD 26.77 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shanghai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 8.41B | 15.2x | 0.65 | USD 6.83 | -11.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sino Biopharma ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 8.26B | 33.5x | USD 8.79 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
CSPC Pharmaceutical Group | OTC Markets | Healthcare | Pharmaceuticals | USD 7.80B | 13.4x | -0.52 | USD 0.64 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion ADR | OTC Markets | Healthcare | Pharmaceuticals | USD 7.64B | 20.4x | 0.39 | USD 26.83 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |